<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342171</url>
  </required_header>
  <id_info>
    <org_study_id>ITM0614</org_study_id>
    <nct_id>NCT02342171</nct_id>
  </id_info>
  <brief_title>Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea</brief_title>
  <acronym>Ebola-Tx</acronym>
  <official_title>Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Blood Transfusion Centre (NBTC), Conakry, Guinea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gamal Abdel Nasser University of Conakry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Training and Research of Maferinyah, Guinea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aix Marseille Université</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UBIVE, Institut Pasteur, Paris, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Belgian Red Cross</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur, Dakar, Sénégal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Médecins Sans Frontières, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Severe Acute Respiratory and Emerging Infection Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Tropical Medicine, Belgium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an emergency, phase 2/3, open-label, non-randomized, clinical trial that will
      evaluate Convalescent Plasma (CP) added to standardized supportive care (SC) in patients with
      confirmed Ebola Virus Disease (EVD). No patient will be refused CP when compatible products
      are available and all efforts will be made to maximize CP availability during the study. EVD
      patients recruited during the period before CP becomes available or for whom no compatible CP
      is available will be given SC and will be followed for study outcomes. Data from these SC
      patients will be the used as comparator in the analysis of the study. The primary objective
      of the study is to assess if CP + SC improves the 14 day survival of patients, compared to SC
      alone.

      The Investigators aim to enroll a total number of 130 - 200 patients who will be treated
      treated with CP assuming equal numbers of patients treated with SC alone. If there would be
      insufficient patients treated with SC, patients treated at the research site prior to study
      start may be included in the comparison group.

      Patients will be recruited in the Ebola Treatment centre managed by Medecins Sans Frontieres
      (MSF) in Conakry, Guinea. All patients and/or relatives presenting at the centre will be
      informed about the study, and will be invited to provide consent at the time of admission
      inside the treatment centre. Only patients for whom ebola infection is confirmed with
      polymerase chain reaction (PCR) will be enrolled in the study. After inclusion, eligibility
      to the intervention will be reassessed on regular intervals. If the eligibility criteria are
      not met by 48 hours after inclusion, only SC will be continued.

      In line with the guidance of the World Health Organization (WHO), two units of CP will be
      given. EVD patients will be transfused with ABO-compatible CP using standard procedures.
      Details on the modalities of transfusion can be found in the WHO guidance document and the
      MSF guidelines on blood transfusion. All patients will be under close observation for
      transfusion-related adverse reactions during and up to 4 hours after transfusion. 24 hours
      after the start of transfusion, a blood sample will be collected for viral load assessment.
      All other aspects of patient management will be according to MSF clinical guidelines. The
      decision to discharge a patient should be taken on clinical grounds, but can be supported by
      the laboratory results. After discharge, the patient will be followed up by the study team
      until day 30.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      West-Africa is being ravaged by the worst outbreak of Ebola Viral Disease (EVD) ever
      witnessed. Nine months after its onset, the outbreak has spiraled and currently appears to be
      out of control. One of the key factors contributing to the high mortality is the lack of any
      proven effective EVD specific treatment. The identification of effective therapies is a
      medical and public health priority. Convalescent whole blood (CWB) and convalescent plasma
      (CP) have been prioritized by the World Health Organization (WHO) to be evaluated within a
      short time span, so that widespread use for therapy could be implemented rapidly if proven
      effective. Both CWB and CP contain EBV antibodies and either could potentially be of value as
      EVD therapy, however their efficacy in Ebola must still be demonstrated. .

      This is an emergency, phase 2/3, open-label, non-randomized, clinical trial that will
      evaluate CP added to standardized supportive care (SC) in patients with confirmed EVD. No
      patient will be refused CP when compatible products are available and all efforts will be
      made to maximize CP availability during the study. EVD patients recruited during the period
      before CP becomes available or for whom no compatible CP is available will be given SC and
      will be followed for study outcomes. Data from these SC patients will be the used as
      comparator in the analysis of the study.

      The primary objective of the study is to assess if CP + SC improves the 14 day survival of
      patients, compared to SC alone. Secondary objectives are;

        -  to assess 30 day survival on CP + SC

        -  to assess the relationship between EV antibody levels in donated CP and survival in
           patients receiving CP

        -  to assess the relationship between EV antibody levels in donated CP and changes in
           levels of viral RNA in the blood of patients receiving CP

        -  to assess the occurrence of serious adverse reactions (SARs) related to CP transfusion
           in Ebola patients

        -  to assess the occurrence of safety risks related to CP transfusion in health workers
           administering the treatments

        -  to determine risk factors for mortality despite administration of CP (for identification
           of patients most likely to benefit)

      The Investigators aim to enroll a total number of 130 - 200 patients treated with CP assuming
      equal numbers of patients treated with SC alone. The number of patients treated with SC will
      be determined by the time interval for CP to become available for treatment and the
      availability of CP throughout the study. If there would be insufficient patients treated with
      SC, patients treated at the research site prior to study start may be included in the
      comparison group.

      Patients will be recruited in the Ebola Treatment centre managed by Medecins Sans Frontieres
      (MSF) in Conakry. All patients and/or relatives presenting at the centre will be informed
      about the study, and will be invited to provide consent at the time of admission inside the
      treatment centre. Only patients for whom ebola infection is confirmed via polymerase chain
      reaction (PCR) will be enrolled in the study. After inclusion, eligibility to the
      intervention will be assessed at the time of enrollment (when the patient is moved to the
      area for patients with confirmed Ebola) and will be reassessed on regular intervals as long
      as the patient did not receive plasma transfusion. The re-assessment of eligibility to
      receive CP happens at 8h and at 12h, and is repeated until 48 hours after inclusion. If the
      eligibility criteria are not met by 48 hours after inclusion, only SC will be continued.

      A patient is not eligible to receive CP if they meet one of the following criteria:

        -  History of allergic reaction to blood or plasma products (as judged by the investigator
           or treating physician); (this first criterion is definite and will not be re-assessed)

        -  Medical conditions in which receipt of additional fluid related to the transfusion
           (250-500 ml or in the case of children 10 ml/kg) may be detrimental to the patient (e.g.
           decompensated congestive heart failure or renal failure).

        -  Patients in shock unresponsive to fluid challenge

        -  Patients in shock with signs of multi-organ failure, defined as oliguria/anuria AND
           impaired consciousness AND/OR jaundice

        -  Condition of patient where the procedure of plasma administration carries a risk for the
           staff

      In line with the WHO guidance, two units of CP will be given. EVD patients will be transfused
      with ABO-compatible CP using standard procedures. Details on the modalities of transfusion
      can be found in the WHO guidance document and the MSF guidelines on blood transfusion. All
      patients will be under close observation for transfusion-related adverse reactions during and
      up to 4 hours after transfusion. 24 hours after the start of transfusion, a blood sample will
      be collected for viral load assessment. All other aspects of patient management will be
      according to MSF clinical guidelines.

      The decision to discharge a patient should be taken on clinical grounds, but can be supported
      by the laboratory results. After discharge, the patient will be followed up by the study team
      until day 30.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at Day 14 After Start of Intervention</measure>
    <time_frame>14 days</time_frame>
    <description>Effect of convalescent plasma in improving patients survival at day 14; it will be considered clinically significant if there is an absolute decrease in the case fatality rate of 20% or more, compared to SC alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 30 Days Survival</measure>
    <time_frame>30 days</time_frame>
    <description>Effect of convalescent plasma in improving patients survival at day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of Ebola Viral RNA</measure>
    <time_frame>30 days</time_frame>
    <description>To assess the relationship between EVD antibody levels (EBOV IgG) in donated plasma and the changes in levels of viral RNA in patients who received Convalescent Plasma.
The outcome shows the overall association between antibody dose category and change in Cycle threshold (Ct) value pre and post transfusion (Ct is the number of cycles that have to be run before reaching a threshold value of a positive result).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of Ebola Viral RNA</measure>
    <time_frame>30 days</time_frame>
    <description>To assess the relationship between EVD antibody levels (neutralizing antibodies) in donated plasma and the changes in levels of viral RNA in patients who received Convalescent Plasma.
The outcome shows the overall association between antibody dose category and change in Cycle threshold (Ct) value pre and post transfusion (Ct is the number of cycles that have to be run before reaching a threshold value of a positive result).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died Corresponding to EV Antibody Levels (Anti-EBOV IgG)</measure>
    <time_frame>14 days</time_frame>
    <description>To assess the relationship between EVD antibody levels (anti-EBOV IgG) and death in patients who received Convalescent Plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died Corresponding to EV Antibody Levels (Neutralizing Antibodies)</measure>
    <time_frame>14 days</time_frame>
    <description>To assess the relationship between EVD antibody levels (neutralizing antibodies) and death in patients who received CP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Transfusion-related Serious Adverse Reactions (SARs)</measure>
    <time_frame>30 days</time_frame>
    <description>To assess the occurrence of serious adverse reactions (SARs) related to CP transfusion in Ebola patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Professional Safety Incidents</measure>
    <time_frame>9 months</time_frame>
    <description>To assess the occurrence of safety risks related to CP transfusion in health workers administering the treatments. This will be observed throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Risk Factor: Ct</measure>
    <time_frame>30 days</time_frame>
    <description>To determine Ct as risk factor for mortality despite administration of CP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Risk Factor: Age</measure>
    <time_frame>30 days</time_frame>
    <description>To determine age as risk factor for mortality despite administration of CP.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">606</enrollment>
  <condition>Hemorrhagic Fever, Ebola</condition>
  <arm_group>
    <arm_group_label>Convalescent Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control arm will consist of historical controls having being treated with standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Convalescent Plasma</intervention_name>
    <description>Patients will be treated with plasma from recovered EVD patients.</description>
    <arm_group_label>Convalescent Plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCR-confirmed, symptomatic infection with Ebola virus

          -  Patient's, guardian's or representatives' willingness to provide written informed
             consent

        Exclusion Criteria:

        A patient is not eligible to receive CP if they meet one of the following criteria:

          -  History of allergic reaction to blood or plasma products (as judged by the
             investigator or treating physician);

          -  Medical conditions in which receipt of additional fluid related to the transfusion
             (250-500 ml or in the case of children 10 ml/kg) may be detrimental to the patient
             (e.g. decompensated congestive heart failure or renal failure).

          -  Patients in shock unresponsive to fluid challenge

          -  Patients in shock with signs of multi-organ failure, defined as oliguria/anuria AND
             impaired consciousness AND/OR jaundice

          -  Condition of patient where the procedure of plasma administration carries a risk for
             the staff
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan van Griensven, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ITM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niankoye Haba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Blood Transfusion Centre (NBTC), Conakry, Guinea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ebola Treatment Center</name>
      <address>
        <city>Donka</city>
        <country>Guinea</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guinea</country>
  </location_countries>
  <results_reference>
    <citation>van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, Haba N; Ebola-Tx Consortium. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med. 2016 Jan 7;374(1):33-42. doi: 10.1056/NEJMoa1511812.</citation>
    <PMID>26735992</PMID>
  </results_reference>
  <results_reference>
    <citation>van Griensven J, Edwards T, Baize S; Ebola-Tx Consortium. Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies. N Engl J Med. 2016 Dec 8;375(23):2307-2309. doi: 10.1056/NEJMc1609116. Epub 2016 Nov 14.</citation>
    <PMID>27959686</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <results_first_submitted>December 14, 2017</results_first_submitted>
  <results_first_submitted_qc>April 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2019</results_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebola Viral Disease</keyword>
  <keyword>Convalescent Plasma</keyword>
  <keyword>Developing Countries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Convalescent Plasma</title>
          <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
        </group>
        <group group_id="P2">
          <title>Standard Care</title>
          <description>The control arm will consist of historical controls having being treated with standard of care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="507"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="418"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received favipiravir</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing cycle treshold value</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown outcome</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing age data</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Convalescent Plasma</title>
          <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
        </group>
        <group group_id="B2">
          <title>Standard Care</title>
          <description>The control arm will consist of historical controls having being treated with standard of care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="418"/>
            <count group_id="B3" value="502"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="0" upper_limit="75"/>
                    <measurement group_id="B2" value="28" lower_limit="0" upper_limit="87"/>
                    <measurement group_id="B3" value="28" lower_limit="0" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;5 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5-15 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>16-44 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;45 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="258"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cycle-threshold on PCR</title>
          <description>The value represents the number of cycles the PCR has run before reaching a threshold value of a positive result.</description>
          <units>Number of cycles</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" lower_limit="19.2" upper_limit="35.8"/>
                    <measurement group_id="B2" value="26.0" lower_limit="15.2" upper_limit="39.4"/>
                    <measurement group_id="B3" value="26.3" lower_limit="15.2" upper_limit="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants per PCR Cycle-threshold interval</title>
          <description>The value represents the number of cycles the PCR has run before reaching a threshold value of a positive result.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;25 cycles</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>25.0-29.9 cycles</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;29.9 cycles</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nausea and vomiting</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diarrhea</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weakness or asthenia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="353"/>
                    <measurement group_id="B3" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="342"/>
                    <measurement group_id="B3" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cough</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Difficulty breathing</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Difficulty swallowing</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hiccups</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eye redness</title>
          <description>Includes both conjunctivitis and conjunctival bleeding</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unusual bleeding</title>
          <description>Excluding conjunctival bleeding</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disorientation or agitation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anuria</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Seizures</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of symptoms &gt;6 days</title>
          <population>Only including patients with any symptom at baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="412"/>
                    <count group_id="B3" value="485"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coexisting chronic medical condition</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Infectious</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noninfectious</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="84"/>
                    <count group_id="B2" value="418"/>
                    <count group_id="B3" value="502"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival at Day 14 After Start of Intervention</title>
        <description>Effect of convalescent plasma in improving patients survival at day 14; it will be considered clinically significant if there is an absolute decrease in the case fatality rate of 20% or more, compared to SC alone</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Convalescent Plasma</title>
            <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>The control arm will consist of historical controls having being treated with standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Survival at Day 14 After Start of Intervention</title>
          <description>Effect of convalescent plasma in improving patients survival at day 14; it will be considered clinically significant if there is an absolute decrease in the case fatality rate of 20% or more, compared to SC alone</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 30 Days Survival</title>
        <description>Effect of convalescent plasma in improving patients survival at day 30</description>
        <time_frame>30 days</time_frame>
        <population>Outcome was only measured in the intervention group. Data (historical) not available for &quot;Standard care&quot; group.</population>
        <group_list>
          <group group_id="O1">
            <title>Convalescent Plasma</title>
            <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 30 Days Survival</title>
          <description>Effect of convalescent plasma in improving patients survival at day 30</description>
          <population>Outcome was only measured in the intervention group. Data (historical) not available for &quot;Standard care&quot; group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titer of Ebola Viral RNA</title>
        <description>To assess the relationship between EVD antibody levels (EBOV IgG) in donated plasma and the changes in levels of viral RNA in patients who received Convalescent Plasma.
The outcome shows the overall association between antibody dose category and change in Cycle threshold (Ct) value pre and post transfusion (Ct is the number of cycles that have to be run before reaching a threshold value of a positive result).</description>
        <time_frame>30 days</time_frame>
        <population>Total dose for antibody levels was categorized in three equal-sized groups (tertiles), with the lowest dose category as reference.
71 out of 84 participants were defined as the analysis population. Children (&lt;16 years) were excluded from the analysis as dosing of CP was done according to body weight, which was not recorded for many adult patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Convalescent Plasma</title>
            <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Titer of Ebola Viral RNA</title>
          <description>To assess the relationship between EVD antibody levels (EBOV IgG) in donated plasma and the changes in levels of viral RNA in patients who received Convalescent Plasma.
The outcome shows the overall association between antibody dose category and change in Cycle threshold (Ct) value pre and post transfusion (Ct is the number of cycles that have to be run before reaching a threshold value of a positive result).</description>
          <population>Total dose for antibody levels was categorized in three equal-sized groups (tertiles), with the lowest dose category as reference.
71 out of 84 participants were defined as the analysis population. Children (&lt;16 years) were excluded from the analysis as dosing of CP was done according to body weight, which was not recorded for many adult patients.</population>
          <units>Cycles</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lowest dose (antibody range 176.4 - 511.9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle dose (antibody range 513.3 - 740.6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" lower_limit="0.87" upper_limit="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Highest dose (antibody range 747.9 - 1628.7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" lower_limit="-0.09" upper_limit="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titer of Ebola Viral RNA</title>
        <description>To assess the relationship between EVD antibody levels (neutralizing antibodies) in donated plasma and the changes in levels of viral RNA in patients who received Convalescent Plasma.
The outcome shows the overall association between antibody dose category and change in Cycle threshold (Ct) value pre and post transfusion (Ct is the number of cycles that have to be run before reaching a threshold value of a positive result).</description>
        <time_frame>30 days</time_frame>
        <population>Total dose for antibody levels was categorized in three equal-sized groups (tertiles), with the lowest dose category as reference.
71 out of 84 participants were defined as the analysis population. Children (&lt;16 years) were excluded from the analysis as dosing of CP was done according to body weight, which was not recorded for many adult patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Convalescent Plasma</title>
            <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Titer of Ebola Viral RNA</title>
          <description>To assess the relationship between EVD antibody levels (neutralizing antibodies) in donated plasma and the changes in levels of viral RNA in patients who received Convalescent Plasma.
The outcome shows the overall association between antibody dose category and change in Cycle threshold (Ct) value pre and post transfusion (Ct is the number of cycles that have to be run before reaching a threshold value of a positive result).</description>
          <population>Total dose for antibody levels was categorized in three equal-sized groups (tertiles), with the lowest dose category as reference.
71 out of 84 participants were defined as the analysis population. Children (&lt;16 years) were excluded from the analysis as dosing of CP was done according to body weight, which was not recorded for many adult patients.</population>
          <units>Cycles</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lowest dose ((antibody range 176.4 - 511.9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle dose (antibody range 513.3 - 740.6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="-2.30" upper_limit="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Highest dose (antibody range 747.9 - 1628.7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" lower_limit="-2.99" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died Corresponding to EV Antibody Levels (Anti-EBOV IgG)</title>
        <description>To assess the relationship between EVD antibody levels (anti-EBOV IgG) and death in patients who received Convalescent Plasma</description>
        <time_frame>14 days</time_frame>
        <population>Overall Number of Participants Analyzed divided in 3 equal groups depending on total dose of antibodies. 71 out of 84 participants were defined as the analysis population. Children (&lt;16 years) were excluded from analysis as dosing of CP was done according to body weight, which was not recorded for many adult patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Convalescent Plasma</title>
            <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died Corresponding to EV Antibody Levels (Anti-EBOV IgG)</title>
          <description>To assess the relationship between EVD antibody levels (anti-EBOV IgG) and death in patients who received Convalescent Plasma</description>
          <population>Overall Number of Participants Analyzed divided in 3 equal groups depending on total dose of antibodies. 71 out of 84 participants were defined as the analysis population. Children (&lt;16 years) were excluded from analysis as dosing of CP was done according to body weight, which was not recorded for many adult patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low (antibody range 176.4 - 511.9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium (antibody range 513.3 - 740.6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High (antibody range 747.9 - 1628.7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died Corresponding to EV Antibody Levels (Neutralizing Antibodies)</title>
        <description>To assess the relationship between EVD antibody levels (neutralizing antibodies) and death in patients who received CP</description>
        <time_frame>14 days</time_frame>
        <population>Overall Number of Participants Analyzed divided in 3 equal groups depending on total dose of antibodies. Children (&lt;16 years) were excluded from analysis as dosing of CP was done according to body weight, which was not recorded for many adult patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Convalescent Plasma</title>
            <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died Corresponding to EV Antibody Levels (Neutralizing Antibodies)</title>
          <description>To assess the relationship between EVD antibody levels (neutralizing antibodies) and death in patients who received CP</description>
          <population>Overall Number of Participants Analyzed divided in 3 equal groups depending on total dose of antibodies. Children (&lt;16 years) were excluded from analysis as dosing of CP was done according to body weight, which was not recorded for many adult patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low(antibody range 176.4 - 511.9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium (antibody range 513.3 - 740.6)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High (antibody range 747.9 - 1628.7)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Transfusion-related Serious Adverse Reactions (SARs)</title>
        <description>To assess the occurrence of serious adverse reactions (SARs) related to CP transfusion in Ebola patients</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Convalescent Plasma</title>
            <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Transfusion-related Serious Adverse Reactions (SARs)</title>
          <description>To assess the occurrence of serious adverse reactions (SARs) related to CP transfusion in Ebola patients</description>
          <units>SARs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Professional Safety Incidents</title>
        <description>To assess the occurrence of safety risks related to CP transfusion in health workers administering the treatments. This will be observed throughout the study</description>
        <time_frame>9 months</time_frame>
        <population>Overall Number of Participants Analyzed refers to health workers administering CP; not to the participants receiving CP.</population>
        <group_list>
          <group group_id="O1">
            <title>Convalescent Plasma</title>
            <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Professional Safety Incidents</title>
          <description>To assess the occurrence of safety risks related to CP transfusion in health workers administering the treatments. This will be observed throughout the study</description>
          <population>Overall Number of Participants Analyzed refers to health workers administering CP; not to the participants receiving CP.</population>
          <units>Professional safety incidents</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Risk Factor: Ct</title>
        <description>To determine Ct as risk factor for mortality despite administration of CP.</description>
        <time_frame>30 days</time_frame>
        <population>Pre-specified sub-group comparison</population>
        <group_list>
          <group group_id="O1">
            <title>Convalescent Plasma</title>
            <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>The control arm will consist of historical controls having being treated with standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Risk Factor: Ct</title>
          <description>To determine Ct as risk factor for mortality despite administration of CP.</description>
          <population>Pre-specified sub-group comparison</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10-24.9 cycles</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25-29.9 cycles</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39.9 cycles</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Risk Factor: Age</title>
        <description>To determine age as risk factor for mortality despite administration of CP.</description>
        <time_frame>30 days</time_frame>
        <population>Pre-specified sub-group comparison</population>
        <group_list>
          <group group_id="O1">
            <title>Convalescent Plasma</title>
            <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>The control arm will consist of historical controls having being treated with standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Risk Factor: Age</title>
          <description>To determine age as risk factor for mortality despite administration of CP.</description>
          <population>Pre-specified sub-group comparison</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;5 years old</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-15 years old</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16-44 years old</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;45 years old</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events related to the intervention up to 4 hours after completion of the transfusion. All deaths possibly related to the intervention up to 14 days after completion of the transfusion.</time_frame>
      <desc>Due to the nature of the symptoms of EVD (high mortality rate, hospital admissions, disability and life-threatening conditions), the investigation of safety and tolerability of the intervention will focus on Adverse Reactions.
An Adverse Reaction is any untoward and unintended response in a participant to the study treatment, which is related (or has a reasonable possibility of being related) to any dose of the investigational product administered to that participant.</desc>
      <group_list>
        <group group_id="E1">
          <title>Convalescent Plasma</title>
          <description>Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children &lt;45kg
Convalescent Plasma: Patients will be treated with plasma from recovered EVD patients.
No data from &quot;standard care&quot; group available as this is based on historical data.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in temperature</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching or skin rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There are clear limitations with respect to the use of a historical control group, and we cannot exclude the possibility that unmeasured confounding factors may have biased the mortality comparison.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Dr. Johan van Griensven</name_or_title>
      <organization>Institute of Tropical Medicine</organization>
      <phone>+3232476426</phone>
      <email>jvangriensven@itg.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

